The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Ossami Saidy A, Boumendil A, Dreger P, Stella F, Ram R, Kröger N, Castagna L, Pabst T, Wulf GG, Martin Garcia-Sancho A, Solano C, Stelljes M, Reinhardt HC, Forcade E, von Bonin M, Hilgendorf I, Martínez López J, Bethge W, Bazarbachi A, Sureda A, Schmitz N, Glass B, GOCART initiative, Lymphoma Working Party (LWP) of the EBMT

Open source

DOI: 10.1038/s41409-026-02913-1
Published: 2026 Aug
Container: Bone marrow transplantation
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41409-026-02913-1,
  title = {The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).},
  author = {Ossami Saidy A and Boumendil A and Dreger P and Stella F and Ram R and Kröger N and Castagna L and Pabst T and Wulf GG and Martin Garcia-Sancho A and Solano C and Stelljes M and Reinhardt HC and Forcade E and von Bonin M and Hilgendorf I and Martínez López J and Bethge W and Bazarbachi A and Sureda A and Schmitz N and Glass B and GOCART initiative and Lymphoma Working Party (LWP) of the EBMT},
  year = {2026},
  journal = {Bone marrow transplantation},
  doi = {10.1038/s41409-026-02913-1},
  url = {https://doi.org/10.1038/s41409-026-02913-1}
}

RIS

TY  - JOUR
TI  - The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).
AU  - Ossami Saidy A
AU  - Boumendil A
AU  - Dreger P
AU  - Stella F
AU  - Ram R
AU  - Kröger N
AU  - Castagna L
AU  - Pabst T
AU  - Wulf GG
AU  - Martin Garcia-Sancho A
AU  - Solano C
AU  - Stelljes M
AU  - Reinhardt HC
AU  - Forcade E
AU  - von Bonin M
AU  - Hilgendorf I
AU  - Martínez López J
AU  - Bethge W
AU  - Bazarbachi A
AU  - Sureda A
AU  - Schmitz N
AU  - Glass B
AU  - GOCART initiative
AU  - Lymphoma Working Party (LWP) of the EBMT
PY  - 2026
JO  - Bone marrow transplantation
DO  - 10.1038/s41409-026-02913-1
UR  - https://doi.org/10.1038/s41409-026-02913-1
ER  -

APA

A, O. S., A, B., P, D., F, S., R, R., N, K., L, C., T, P., GG, W., A, M. G., C, S., M, S., HC, R., E, F., M, V. B., I, H., J, M. L., W, B., A, B., A, S., N, S., B, G., initiative, G., & EBMT, L. W. P. (. O. T. (2026). The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).. Bone marrow transplantation. https://doi.org/10.1038/s41409-026-02913-1

Source records

pubmed · retrieved 2026-09-27T13:12:18.274Z